ALDERAAN BIOTECHNOLOGY


Targeting tumor cells & suppressive immune cells

ALDERAAN BIOTECHNOLOGY

Our Vision

Alderaan Biotechnology develops therapeutic modalities targeting CD25 (IL2Ra) and CD160-TM for the treatment of cancers.

The company focuses on an ADC strategy that targets CD25+ cancer cells in Hematologic malignancies using a proprietary IL-2 sparing, CD25-specific antibody. In addition, Alderaan has generated unique proprietary antibodies against CD160-TM, a novel NK cell receptor overexpressed in solid cancers and in NK and T-cell lymphomas and Leukemias.

ALDERAAN BIOTECHNOLOGY

Science

The company programs are based on the research of its founding scientists on the use of monoclonal antibodies targeting immune cells and tumour cells to treat cancers. The objective of Alderaan Biotechnology is to develop new therapeutic modalities targeting CD25, a molecule expressed by both Leukemic/lymphoma cells and suppressive Treg cells and CD160-TM, a novel marker overexpressed in solid tumours, with oncology as the sole indication focus.

CD160TM

Developing “First-In-Class” therapeutic modalities targeting CD160-TM

CD25

Targeting CD25-positive Leukemic Stem cells (LSCs) and triggering Treg depletion using ALD25_ADC

ALDERAAN BIOTECHNOLOGY

News & Events

Alderaan Biotechnology presents latest developments at SITC Congress 329 293 gloria

Alderaan Biotechnology presents latest developments at SITC Congress

Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress. ALD2510 antibody…

read more

Find out all the news of
Alderaan Biotechnology

Twitter feed is not available at the moment.